Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells

Summary

Ruxolitinib will be dispensed to patients candidate to prostatectomy immediately after histological diagnosis of prostate adenocarcinoma. The treatment will be given for 28 days followed by a prostatectomy thereafter. Tumor material and blood samples will be analysed before, during and after the treatment with Ruxolitinib.

Timeline

Start

2017-09-01

Primary completion

2020-03-24

Completion

2020-03-24

Drugs

Indications